BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 5, 2012--
Bruker Corporation (NASDAQ: BRKR) today reported financial results for
the third quarter ended September 30, 2012.
Bruker Corporation Financial Results
In the third quarter of 2012, revenue was $447.8 million, an increase of
7.0% compared to $418.4 million in the third quarter of 2011. Excluding
the effects of acquisitions and foreign currency translation, third
quarter 2012 revenue increased by 13.8% year-over-year. GAAP net income
for the third quarter of 2012 was $39.7 million, or $0.24 per diluted
share, compared to $19.8 million, or $0.12 per diluted share, in the
third quarter of 2011. Adjusted net income for the third quarter of 2012
was $47.1 million, or $0.28 per diluted share, compared to $34.4
million, or $0.21 per diluted share, in the third quarter of 2011.
For the nine months ended September 30, 2012, revenue was $1,274.1
million, an increase of 8.3% compared to $1,176.6 million in the first
nine months of 2011. Excluding the effects of acquisitions and foreign
currency translation, revenue for the first nine months of 2012
increased by 12.6% over the comparable period in 2011. GAAP net income
for the nine months ended September 30, 2012 was $64.7 million, or $0.39
per diluted share, compared to $53.2 million, or $0.32 per diluted
share, for the nine months ended September 30, 2011. Adjusted net income
for the nine months ended September 30, 2012 was $91.6 million, or $0.54
per diluted share, compared to $87.7 million, or $0.53 per diluted
share, for the nine months ended September 30, 2011.
Bruker ended the third quarter of 2012 with cash and cash equivalents of
$242.1 million, and net debt of $94.8 million.
Adjusted operating margin, adjusted net income and adjusted EPS are
non-GAAP measures that exclude certain items detailed later in this
press release under the heading “Use of Non-GAAP Financial Measures.”
Bruker Scientific Instruments (BSI) Segment
In the third quarter of 2012, BSI revenue was $408.9 million, an
increase of 3.6% compared to $394.6 million for the third quarter of
2011. Excluding the effects of acquisitions and foreign currency
translation, BSI revenue for the third quarter of 2012 increased by 9.5%
over the third quarter of 2011. BSI segment GAAP EPS in the third
quarter of 2012 was $0.19 per diluted share, compared to $0.15 in the
third quarter of 2011. BSI segment adjusted EPS in the third quarter of
2012 was $0.23 per diluted share, compared to $0.22 in the third quarter
of 2011.
For the nine months ended September 30, 2012, BSI revenue was $1,184.0
million, an increase of 6.8% compared to $1,108.3 million in the first
nine months of 2011. Excluding the effects of acquisitions and foreign
currency translation, BSI revenue for the first nine months of 2012
increased by 10.6% over the comparable period in 2011. BSI segment GAAP
EPS for the nine months ended September 30, 2012 was $0.35 per diluted
share, compared to $0.37 for the nine months ended September 30, 2011.
BSI segment adjusted EPS for the nine months ended September 30, 2012
was $0.49 per diluted share, compared to $0.56 for the comparable period
in 2011.
Bruker Energy & Supercon Technologies (BEST) Segment
In the third quarter of 2012, BEST revenue was $42.4 million, an
increase of 53.1% compared to $27.7 million for the third quarter of
2011. Excluding the effects of foreign currency translation, BEST
revenue for the third quarter of 2012 increased by 72.6% over the third
quarter of 2011. Third quarter 2012 BEST revenue included $16.4 million
from the previously announced Rosatom contract. BEST segment GAAP EPS in
the third quarter of 2012 was $0.06, compared to a GAAP loss per diluted
share of ($0.03) in the third quarter of 2011. BEST segment adjusted EPS
in the third quarter of 2012 was $0.06, compared to an adjusted net loss
per diluted share of ($0.01) in the third quarter of 2011.
For the nine months ended September 30, 2012, revenue for BEST was $98.4
million, an increase of 23.3% compared to $79.8 million in the first
nine months of 2011. Excluding the effects of foreign currency
translation, BEST revenue for the first nine months of 2012 increased by
35.5% over the comparable period in 2011. BEST segment GAAP EPS for the
nine months ended September 30, 2012 was $0.05, compared to a loss per
diluted share of ($0.04) for the nine months ended September 30, 2011.
BEST segment adjusted EPS for the nine months ended September 30, 2012
was $0.06, compared to an adjusted net loss per diluted share of ($0.02)
for the comparable period in 2011.
Comment and Outlook
Frank Laukien, President and CEO of Bruker Corporation, commented:
“Despite continued softening of demand in certain markets, we are
pleased with our double-digit third quarter 2012 organic revenue growth
rate, which in part benefitted from our still very significant backlog.
Profitability also improved in the third quarter year-over-year. As a
result of our third quarter performance, we are raising our full-year
2012 revenue guidance to a range of $1.73 - $1.76 billion, and we are
raising our full-year adjusted EPS guidance to $0.75 - $0.79 per diluted
share.”
Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with
generally accepted accounting principles (GAAP), we use certain non-GAAP
financial measures, including organic revenue growth, adjusted EPS,
adjusted operating income, adjusted net income and adjusted operating
margin, which exclude acquisition-related and restructuring and other
charges. We exclude the above items because they are outside of our
normal operations and/or, in certain cases, are difficult to forecast
accurately for future periods. We believe that the use of non-GAAP
measures helps investors to gain a better understanding of our core
operating results and future prospects, consistent with how management
measures and forecasts the company’s performance, especially when
comparing such results to previous periods or guidance.
For example:
We exclude certain acquisition-related charges or credits and associated
tax effects, including charges for the sale of inventories revalued at
the date of acquisition, significant transaction costs such as legal
fees and credits associated with bargain purchases. We exclude these
costs because we do not believe they are indicative of our normal
operating costs.
We exclude charges and tax effects associated with restructuring and
business divestiture activities, such as reducing overhead and
consolidating facilities. We believe that the costs related to these
restructuring and business divestiture activities are not indicative of
our normal operating costs.
We exclude the expense and tax effects associated with the amortization
of acquisition-related intangible assets because a significant portion
of the purchase price for acquisitions may be allocated to intangible
assets that have lives of 3 to 12 years. Exclusion of these non-cash
amortization expenses allows comparisons of operating results that are
consistent over time for both our newly acquired and long-held
businesses.
Bruker’s management uses these non-GAAP measures, in addition to GAAP
financial measures, as the basis for measuring the company’s core
operating performance and comparing such performance to that of prior
periods and to the performance of our competitors. Such measures are
also used by management in their financial and operating decision-making
and for compensation purposes.
The non-GAAP financial measures of Bruker’s results of operations
included in this press release are not meant to be considered superior
to or a substitute for Bruker’s results of operations prepared in
accordance with GAAP. Reconciliations of such non-GAAP financial
measures to the most directly comparable GAAP financial measures are set
forth in the accompanying tables.
EARNINGS CONFERENCE CALL
Bruker Corporation will host an operator-assisted earnings conference
call at 9:00 a.m. Eastern Time on Monday, November 5, 2012. To listen to
the webcast, investors can go to http://ir.bruker.com
and click on the live web broadcast symbol. The webcast will be
available through the Company web site for 30 days. Investors can also
listen and participate on the telephone in the US and Canada by calling
800-688-0796, or +1-617-614-4070 outside the US and Canada. Investors
should refer to the Bruker Earnings Call. A telephone replay of the
conference call will be available one hour after the conference call by
dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside
the US and Canada, and then entering replay pass code 75969744. For more
information, please visit http://ir.bruker.com.
CAUTIONARY STATEMENT OF BRUKER CORPORATION
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those projected,
including, but not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility in
the capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product development
and market acceptance of our products, the cost and pricing of our
products, manufacturing, competition, dependence on collaborative
partners and key suppliers, capital spending and government funding
policies, the outcome of any actions that may be taken by government
agencies in connection with FCPA compliance matters we have disclosed to
them, changes in governmental regulations, realization of anticipated
benefits from economic stimulus programs, intellectual property rights,
litigation, and exposure to foreign currency fluctuations and other risk
factors discussed from time to time in our filings with the Securities
and Exchange Commission. These and other factors are identified and
described in more detail in our filings with the SEC, including, without
limitation, our annual report on Form 10-K for the year ended December
31, 2011, our most recent quarterly report on Form 10-Q and our current
reports on Form 8-K. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by law.
|
|
|
Bruker Corporation
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
(in millions, except per share amounts)
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
|
|
|
2012
|
|
|
|
2011
|
|
|
|
2012
|
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
$
|
447.8
|
|
|
$
|
418.4
|
|
|
$
|
1,274.1
|
|
|
$
|
1,176.6
|
|
|
Cost of revenues
|
|
|
|
237.2
|
|
|
|
229.0
|
|
|
|
684.9
|
|
|
|
641.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
210.6
|
|
|
|
189.4
|
|
|
|
589.2
|
|
|
|
534.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
|
102.9
|
|
|
|
102.1
|
|
|
|
317.9
|
|
|
|
289.6
|
|
|
Research and development
|
|
|
|
44.9
|
|
|
|
43.5
|
|
|
|
145.0
|
|
|
|
132.5
|
|
|
Write-off of deferred offering costs
|
|
|
|
-
|
|
|
|
3.4
|
|
|
|
-
|
|
|
|
3.4
|
|
|
Other charges, net
|
|
|
|
2.5
|
|
|
|
2.9
|
|
|
|
9.5
|
|
|
|
7.4
|
|
|
Total operating expenses
|
|
|
|
150.3
|
|
|
|
151.9
|
|
|
|
472.4
|
|
|
|
432.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
60.3
|
|
|
|
37.5
|
|
|
|
116.8
|
|
|
|
101.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and other income (expense), net
|
|
|
|
(2.7
|
)
|
|
|
1.9
|
|
|
|
(13.0
|
)
|
|
|
(8.8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes and noncontrolling
|
|
|
|
|
|
|
|
|
|
|
|
|
interest in consolidated subsidiaries
|
|
|
|
57.6
|
|
|
|
39.4
|
|
|
|
103.8
|
|
|
|
93.1
|
|
|
Income tax provision
|
|
|
|
17.7
|
|
|
|
19.3
|
|
|
|
38.9
|
|
|
|
38.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net income
|
|
|
|
39.9
|
|
|
|
20.1
|
|
|
|
64.9
|
|
|
|
54.4
|
|
|
Net income attributable to noncontrolling
|
|
|
|
|
|
|
|
|
|
|
|
|
interests in consolidated subsidiaries
|
|
|
|
0.2
|
|
|
|
0.3
|
|
|
|
0.2
|
|
|
|
1.2
|
|
|
Net income attributable to Bruker Corporation
|
|
|
$
|
39.7
|
|
|
$
|
19.8
|
|
|
$
|
64.7
|
|
|
$
|
53.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share attributable to
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Corporation shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
$
|
0.24
|
|
|
$
|
0.12
|
|
|
$
|
0.39
|
|
|
$
|
0.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
166.0
|
|
|
|
165.6
|
|
|
|
165.9
|
|
|
|
165.4
|
|
|
|
Diluted
|
|
|
|
167.3
|
|
|
|
166.9
|
|
|
|
167.3
|
|
|
|
167.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of BSI and BEST reportable segments to the
consolidated results of Bruker Corporation for the three and nine months
ended September 30, 2012 and 2011 (unaudited) (a) (b)
|
Segment Data
|
|
|
|
Bruker
|
|
|
|
|
|
(in millions, except per share amounts)
|
|
Bruker
|
|
Energy &
|
|
Corporate,
|
|
Consolidated
|
|
|
|
Scientific
|
|
Supercon
|
|
Adjustments
|
|
Bruker
|
|
Three Months Ended September 30, 2012:
|
|
Instruments
|
|
Technologies
|
|
& Eliminations
|
|
Corporation
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
408.9
|
|
|
$
|
42.4
|
|
|
$
|
(3.5
|
)
|
|
$
|
447.8
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit - GAAP (a)
|
|
$
|
191.6
|
|
|
$
|
21.3
|
|
|
$
|
(2.3
|
)
|
|
$
|
210.6
|
|
|
Cost of revenues charges (c)
|
|
|
1.1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.1
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
4.7
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4.7
|
|
|
Gross profit - adjusted (b)
|
|
$
|
197.4
|
|
|
$
|
21.3
|
|
|
$
|
(2.3
|
)
|
|
$
|
216.4
|
|
|
Gross profit margin - adjusted (b)
|
|
|
48.3
|
%
|
|
|
50.2
|
%
|
|
|
|
|
48.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) - GAAP (a)
|
|
$
|
48.0
|
|
|
$
|
14.4
|
|
|
$
|
(2.1
|
)
|
|
$
|
60.3
|
|
|
Cost of revenues charges (c)
|
|
|
1.1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.1
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
5.5
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5.5
|
|
|
Other charges (e)
|
|
|
2.2
|
|
|
|
0.3
|
|
|
|
-
|
|
|
|
2.5
|
|
|
Operating income (loss) - adjusted (b)
|
|
$
|
56.8
|
|
|
$
|
14.7
|
|
|
$
|
(2.1
|
)
|
|
$
|
69.4
|
|
|
Operating margin - adjusted (b)
|
|
|
13.9
|
%
|
|
|
34.7
|
%
|
|
|
|
|
15.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - GAAP (a)
|
|
$
|
31.0
|
|
|
$
|
10.4
|
|
|
$
|
(1.7
|
)
|
|
$
|
39.7
|
|
|
Cost of revenues charges (c)
|
|
|
1.1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.1
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
5.2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5.2
|
|
|
Other charges (e)
|
|
|
0.8
|
|
|
|
0.3
|
|
|
|
-
|
|
|
|
1.1
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - adjusted (b)
|
|
$
|
38.1
|
|
|
$
|
10.7
|
|
|
$
|
(1.7
|
)
|
|
$
|
47.1
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - GAAP (a)
|
|
$
|
0.19
|
|
|
$
|
0.06
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.24
|
|
|
Cost of revenues charges (c)
|
|
|
0.01
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.01
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
0.03
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.03
|
|
|
Other charges (e)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - adjusted (b)
|
|
$
|
0.23
|
|
|
$
|
0.06
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.28
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
167.3
|
|
|
|
167.3
|
|
|
|
166.0
|
|
|
|
167.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2011:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
394.6
|
|
|
$
|
27.7
|
|
|
$
|
(3.9
|
)
|
|
$
|
418.4
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit - GAAP (a)
|
|
$
|
184.5
|
|
|
$
|
5.4
|
|
|
$
|
(0.5
|
)
|
|
$
|
189.4
|
|
|
Cost of revenues charges (c)
|
|
|
1.3
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.3
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
4.1
|
|
|
|
0.1
|
|
|
|
-
|
|
|
|
4.2
|
|
|
Gross profit - adjusted (b)
|
|
$
|
189.9
|
|
|
$
|
5.5
|
|
|
$
|
(0.5
|
)
|
|
$
|
194.9
|
|
|
Gross profit margin - adjusted (b)
|
|
|
48.1
|
%
|
|
|
19.9
|
%
|
|
|
|
|
46.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) - GAAP (a)
|
|
$
|
41.3
|
|
|
$
|
(3.3
|
)
|
|
$
|
(0.5
|
)
|
|
$
|
37.5
|
|
|
Cost of revenues charges (c)
|
|
|
1.3
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.3
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
4.9
|
|
|
|
0.1
|
|
|
|
-
|
|
|
|
5.0
|
|
|
Other charges (e)
|
|
|
2.9
|
|
|
|
3.4
|
|
|
|
-
|
|
|
|
6.3
|
|
|
Operating income (loss) - adjusted (b)
|
|
$
|
50.4
|
|
|
$
|
0.2
|
|
|
$
|
(0.5
|
)
|
|
$
|
50.1
|
|
|
Operating margin - adjusted (b)
|
|
|
12.8
|
%
|
|
|
0.7
|
%
|
|
|
|
|
12.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - GAAP (a)
|
|
$
|
25.7
|
|
|
$
|
(4.8
|
)
|
|
$
|
(1.1
|
)
|
|
$
|
19.8
|
|
|
Cost of revenues charges (c)
|
|
|
0.9
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.9
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
4.8
|
|
|
|
0.1
|
|
|
|
-
|
|
|
|
4.9
|
|
|
Other charges (e)
|
|
|
5.4
|
|
|
|
3.4
|
|
|
|
-
|
|
|
|
8.8
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - adjusted (b)
|
|
$
|
36.8
|
|
|
$
|
(1.3
|
)
|
|
$
|
(1.1
|
)
|
|
$
|
34.4
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - GAAP (a)
|
|
$
|
0.15
|
|
|
$
|
(0.03
|
)
|
|
$
|
-
|
|
|
$
|
0.12
|
|
|
Cost of revenues charges (c)
|
|
|
0.01
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.01
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
0.03
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.03
|
|
|
Other charges (e)
|
|
|
0.03
|
|
|
|
0.02
|
|
|
|
-
|
|
|
|
0.05
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - adjusted (b)
|
|
$
|
0.22
|
|
|
$
|
(0.01
|
)
|
|
$
|
-
|
|
|
$
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
166.9
|
|
|
|
165.6
|
|
|
|
165.6
|
|
|
|
166.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Data
|
|
|
|
Bruker
|
|
|
|
|
|
(in millions, except per share amounts)
|
|
Bruker
|
|
Energy &
|
|
Corporate,
|
|
Consolidated
|
|
|
|
Scientific
|
|
Supercon
|
|
Adjustments
|
|
Bruker
|
|
Nine Months Ended September 30, 2012:
|
|
Instruments
|
|
Technologies
|
|
& Eliminations
|
|
Corporation
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
1,184.0
|
|
|
$
|
98.4
|
|
|
$
|
(8.3
|
)
|
|
$
|
1,274.1
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit - GAAP (a)
|
|
$
|
558.1
|
|
|
$
|
34.1
|
|
|
$
|
(3.0
|
)
|
|
$
|
589.2
|
|
|
Cost of revenues charges (c)
|
|
|
3.5
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3.5
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
13.5
|
|
|
|
0.2
|
|
|
|
-
|
|
|
|
13.7
|
|
|
Gross profit - adjusted (b)
|
|
$
|
575.1
|
|
|
$
|
34.3
|
|
|
$
|
(3.0
|
)
|
|
$
|
606.4
|
|
|
Gross profit margin - adjusted (b)
|
|
|
48.6
|
%
|
|
|
34.9
|
%
|
|
|
|
|
47.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) - GAAP (a)
|
|
$
|
106.3
|
|
|
$
|
13.4
|
|
|
$
|
(2.9
|
)
|
|
$
|
116.8
|
|
|
Cost of revenues charges (c)
|
|
|
3.5
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3.5
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
16.0
|
|
|
|
0.2
|
|
|
|
-
|
|
|
|
16.2
|
|
|
Other charges (e)
|
|
|
8.1
|
|
|
|
1.4
|
|
|
|
-
|
|
|
|
9.5
|
|
|
Operating income (loss) - adjusted (b)
|
|
$
|
133.9
|
|
|
$
|
15.0
|
|
|
$
|
(2.9
|
)
|
|
$
|
146.0
|
|
|
Operating margin - adjusted (b)
|
|
|
11.3
|
%
|
|
|
15.2
|
%
|
|
|
|
|
11.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - GAAP (a)
|
|
$
|
58.2
|
|
|
$
|
8.9
|
|
|
$
|
(2.4
|
)
|
|
$
|
64.7
|
|
|
Cost of revenues charges (c)
|
|
|
3.3
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3.3
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
15.4
|
|
|
|
0.2
|
|
|
|
-
|
|
|
|
15.6
|
|
|
Other charges (e)
|
|
|
6.6
|
|
|
|
1.4
|
|
|
|
-
|
|
|
|
8.0
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - adjusted (b)
|
|
$
|
83.5
|
|
|
$
|
10.5
|
|
|
$
|
(2.4
|
)
|
|
$
|
91.6
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - GAAP (a)
|
|
$
|
0.35
|
|
|
$
|
0.05
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.39
|
|
|
Cost of revenues charges (c)
|
|
|
0.02
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.02
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
0.09
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.09
|
|
|
Other charges (e)
|
|
|
0.03
|
|
|
|
0.01
|
|
|
|
-
|
|
|
|
0.04
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - adjusted (b)
|
|
$
|
0.49
|
|
|
$
|
0.06
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.54
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
167.3
|
|
|
|
167.3
|
|
|
|
165.9
|
|
|
|
167.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2011:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
1,108.3
|
|
|
$
|
79.8
|
|
|
$
|
(11.5
|
)
|
|
$
|
1,176.6
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit - GAAP (a)
|
|
$
|
521.1
|
|
|
$
|
15.5
|
|
|
$
|
(1.8
|
)
|
|
$
|
534.8
|
|
|
Cost of revenues charges (c)
|
|
|
10.4
|
|
|
|
-
|
|
|
|
-
|
|
|
|
10.4
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
10.7
|
|
|
|
0.3
|
|
|
|
-
|
|
|
|
11.0
|
|
|
Gross profit - adjusted (b)
|
|
$
|
542.2
|
|
|
$
|
15.8
|
|
|
$
|
(1.8
|
)
|
|
$
|
556.2
|
|
|
Gross profit margin - adjusted (b)
|
|
|
48.9
|
%
|
|
|
19.8
|
%
|
|
|
|
|
47.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) - GAAP (a)
|
|
$
|
107.3
|
|
|
$
|
(3.6
|
)
|
|
$
|
(1.8
|
)
|
|
$
|
101.9
|
|
|
Cost of revenues charges (c)
|
|
|
10.4
|
|
|
|
-
|
|
|
|
-
|
|
|
|
10.4
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
12.8
|
|
|
|
0.3
|
|
|
|
-
|
|
|
|
13.1
|
|
|
Other charges (e)
|
|
|
7.4
|
|
|
|
3.4
|
|
|
|
-
|
|
|
|
10.8
|
|
|
Operating income (loss) - adjusted (b)
|
|
$
|
137.9
|
|
|
$
|
0.1
|
|
|
$
|
(1.8
|
)
|
|
$
|
136.2
|
|
|
Operating margin - adjusted (b)
|
|
|
12.4
|
%
|
|
|
0.1
|
%
|
|
|
|
|
11.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - GAAP (a)
|
|
$
|
62.2
|
|
|
$
|
(7.2
|
)
|
|
$
|
(1.8
|
)
|
|
$
|
53.2
|
|
|
Cost of revenues charges (c)
|
|
|
8.6
|
|
|
|
-
|
|
|
|
-
|
|
|
|
8.6
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
12.2
|
|
|
|
0.3
|
|
|
|
-
|
|
|
|
12.5
|
|
|
Other charges (e)
|
|
|
10.0
|
|
|
|
3.4
|
|
|
|
-
|
|
|
|
13.4
|
|
|
Net income (loss) attributable
|
|
|
|
|
|
|
|
|
|
to Bruker Corporation - adjusted (b)
|
|
$
|
93.0
|
|
|
$
|
(3.5
|
)
|
|
$
|
(1.8
|
)
|
|
$
|
87.7
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - GAAP (a)
|
|
$
|
0.37
|
|
|
$
|
(0.04
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
0.32
|
|
|
Cost of revenues charges (c)
|
|
|
0.05
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.05
|
|
|
Amortization of acquisition-related intangible assets (d)
|
|
|
0.08
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.08
|
|
|
Other charges (e)
|
|
|
0.06
|
|
|
|
0.02
|
|
|
|
-
|
|
|
|
0.08
|
|
|
Diluted net income (loss) per common share
|
|
|
|
|
|
|
|
|
|
attributable to Bruker Corporation - adjusted (b)
|
|
$
|
0.56
|
|
|
$
|
(0.02
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
167.0
|
|
|
|
165.4
|
|
|
|
165.4
|
|
|
|
167.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) “GAAP” (reported) results were determined in accordance with U.S.
generally accepted accounting principles (GAAP).
(b) Adjusted
results are non-GAAP measures and for income measures exclude certain
charges to cost of revenues (see note c for details); amortization of
acquisition-related intangible assets (see note d for details);
restructuring and other charges (see note e for details); and the tax
consequences of the preceding items.
(c) Reported results in the
three and nine month periods ended September 30, 2012 and 2011 include
charges for the sale of inventories and the depreciation of property,
plant and equipment revalued at the date of acquisition, charges to cost
of goods sold related to certain restructuring programs as well as
charges attributable to manufacturing engineering modifications
associated with certain specialty magnets.
(d) Reported results in
the three and nine month periods ended September 30, 2012 and 2011
include non-cash charges for the amortization of acquisition-related
intangible assets.
(e) Reported results in the three and nine month
periods ended September 30, 2012 and 2011 include certain fees
associated with legal compliance and examinations, acquisition-related
costs and other costs associated with the restructuring and relocation
of certain operations. The three and nine months ended September 30,
2012 also includes a gain on sale of a business. The three and nine
months ended September 30, 2011 also includes deferred BEST public
offering costs that were expensed.
The charges described in notes c, d and e have been tax effected using
enacted tax rates in the jurisdiction in which the charge was recorded.
In addition, reported results for the three and nine months ended
September 30, 2011 include $2.5 million of provisions for income tax
related to historical tax periods under audit.
|
|
|
Bruker Corporation
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
|
|
|
|
|
|
|
|
September 30,
|
|
December 31,
|
|
|
|
|
|
|
2012
|
|
|
|
2011
|
|
|
ASSETS
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
242.1
|
|
|
$
|
246.0
|
|
|
|
Accounts receivable, net
|
|
|
264.8
|
|
|
|
282.8
|
|
|
|
Inventories
|
|
|
632.8
|
|
|
|
576.2
|
|
|
|
Other current assets
|
|
|
105.2
|
|
|
|
89.1
|
|
|
|
|
Total current assets
|
|
|
1,244.9
|
|
|
|
1,194.1
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
272.5
|
|
|
|
249.0
|
|
|
Intangibles, net and other long-term assets
|
|
|
282.6
|
|
|
|
267.4
|
|
|
|
|
Total assets
|
|
$
|
1,800.0
|
|
|
$
|
1,710.5
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
Current portion of long-term debt
|
|
$
|
38.9
|
|
|
$
|
83.7
|
|
|
|
Accounts payable
|
|
|
78.0
|
|
|
|
72.3
|
|
|
|
Customer advances
|
|
|
265.3
|
|
|
|
268.6
|
|
|
|
Other current liabilities
|
|
|
304.3
|
|
|
|
331.2
|
|
|
|
|
Total current liabilities
|
|
|
686.5
|
|
|
|
755.8
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
298.0
|
|
|
|
219.4
|
|
|
Other long-term liabilities
|
|
|
119.8
|
|
|
|
110.4
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' equity:
|
|
|
|
|
|
|
Common stock
|
|
|
1.7
|
|
|
|
1.7
|
|
|
|
Treasury stock
|
|
|
(0.2
|
)
|
|
|
(0.2
|
)
|
|
|
Retained earnings
|
|
|
506.2
|
|
|
|
441.5
|
|
|
|
Other shareholders' equity
|
|
|
185.0
|
|
|
|
178.5
|
|
|
|
|
Total shareholders' equity attributable to Bruker Corporation
|
|
|
692.7
|
|
|
|
621.5
|
|
|
|
Noncontrolling interest in consolidated subsidiaries
|
|
|
3.0
|
|
|
|
3.4
|
|
|
|
|
Total shareholders' equity
|
|
|
695.7
|
|
|
|
624.9
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
|
$
|
1,800.0
|
|
|
$
|
1,710.5
|
|

Source: Bruker Corporation
Bruker Corporation
Stacey Desrochers, +1 978-663-3660, ext. 1115
Director
of Investor Relations
stacey.desrochers@bruker.com